Loading clinical trials...
Loading clinical trials...
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
Conditions
Interventions
Laboratory Biomarker Analysis
Selumetinib Sulfate
Locations
9
United States
Los Angeles County-USC Medical Center
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, United States
NCI - Center for Cancer Research
Bethesda, Maryland, United States
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Start Date
July 21, 2017
Primary Completion Date
August 10, 2018
Completion Date
October 15, 2020
Last Updated
February 9, 2021
NCT02600949
NCT05334069
NCT01660971
NCT02890355
NCT02336087
NCT03257761
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions